Overview

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831

Status:
Enrolling by invitation
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the long-term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder
Phase:
Phase 3
Details
Lead Sponsor:
Alkermes, Inc.